BAX and non-small cell lung carcinoma: Li et al. [56] investigated the function of miR-1244 in DDP therapy for NSCLC and reported that the overexpression of miR-1244 inhibits viability of A549 cells treated with DDP, promotes Caspase-3 activity, and increases p53 and Bax protein expression.